Otonomy shares plunged 50.1 percent at news that the company’s drug to treat Meniere’s disease failed to hit the primary endpoint in a Phase III trial.
Auris Medical AG announced that the Swiss-based company’s Phase III tinnitus trial for Keyzilen failed to meet endpoints.
A sound-emitting device worn in the ear during sleep may train the brain to ignore an annoying chronic ringing in the ears, a new study suggests.
Auris Medical Holding AG said its experimental drug for acute inner ear tinnitus missed the main goals of a late-stage study.
People with tinnitus – a ringing or other “phantom” sounds in their ears – may benefit from a treatment that sends electromagnetic pulses into the brain, suggests a new study. Transcranial magnetic simulation (TMS) is not currently available for the average person with tinnitus, but the study’s lead author hopes it will someday be used […]